Aminoacylase 1 deficiency
Dec. 23, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Monoamine oxidase deficiency
- Updated 05.14.2024
- Released 03.30.1995
- Expires For CME 05.14.2027
Monoamine oxidase deficiency
Introduction
Overview
Monoamine oxidase-A deficiency is an X-linked disorder affecting the catabolism of serotonin and the catecholamines. The main symptoms are mild intellectual disability and behavioral abnormalities consisting of excessive, sometimes violent aggression. Diagnosis may be inferred from a finding of elevated urinary concentrations of the monoamine oxidase-A substrates, normetanephrine, 3-methoxytyramine, and tyramine, in combination with reduced amounts of the monoamine oxidase products, vanillylmandelic acid, homovanillic acid, 3-methoxy-4-hydroxyphenolglycol, and 5-hydroxyindoleacetic acid. Monoamine oxidase deficiency has been found as an isolated defect affecting monoamine oxidase A and, in combination with a deletion of the Norrie disease gene, as a combined deficiency of monoamine oxidase A and B or an isolated deficiency of monoamine oxidase B. Confirmation of monoamine oxidase-A deficiency is obtained by measurement of the activity of this enzyme in dexamethasone-stimulated fibroblasts. Combined monoamine oxidase-A and -B deficiency has similar biochemical consequences. Presentation is with intermittent hypotonia, stereotypic hand movements, and developmental delay.
Key points
• Monoamine oxidase deficiency is inherited as an X-linked trait. | |
• Monoamine oxidase exists in two distinct forms encoded by separate genes, monoamine oxidase-A and monoamine oxidase-B, and each has preferential affinities for biogenic amine and other amine substrates. | |
• Monoamine oxidase deficiency has been described as isolated monoamine oxidase-A deficiency, as a combined monoamine oxidase-A and B deficiency, as a combined monoamine oxidase-A and B deficiency in association with Norrie disease, and as an isolated monoamine oxidase-B deficiency in association with Norrie disease. | |
• Individuals with monoamine oxidase deficiency should avoid foods or drugs containing amines. |
Clinical manifestations
Presentation and course
|
• Deficiency of monoamine oxidase has been described in association with Norrie disease (an X-linked syndrome characterized by congenital blindness, hearing loss, and variable mental retardation), as an isolated defect affecting only monoamine oxidase-A and as a combined deficiency of both monoamine oxidase-A and B in the absence of Norrie disease. | |
|
• The main symptoms of monoamine oxidase-A (MAOA) deficiency ("Brunner syndrome") are mild mental retardation, behavioral abnormalities, and sleep disorders affecting male members. The most prominent behavioral problem was overt antisocial conduct with excessive, sometimes violent aggression, often triggered by anger. | |
|
• The neurochemical and behavioral abnormalities seen in monoamine oxidase-A deficiency were not found in two brothers who had monoamine oxidase-B deficiency associated with Norrie disease. | |
|
• Combined monoamine oxidase-A and B deficiency with Norrie disease often results in growth failure, severe mental retardation, autistic symptoms, and altered sleep patterns. |
Several disorders of monoamine oxidase (MAO) have been described, involving isolated MAO-A deficiency, combined MAO-A and B deficiencies, MAO-B deficiency with Norrie disease, and combined MAO-A and B deficiencies with Norrie disease. In all but the kindreds with isolated MAO-A deficiency, involvement of deletions of the X chromosome in areas other than the structural genes for MAO-A gene and MAO-B impedes interpretation of the clinical data in these kindreds.
Isolated MAO-A deficiency (Brunner syndrome; OMIM 300615). In 1993, Dutch geneticist Han G Brunner and colleagues at the University Hospital Radboud Universiteit (Nijmegen, Netherlands) described a large Dutch kindred with a new form of X-linked, nondysmorphic, mild mental retardation that occurred with marked behavioral abnormalities and sleep disorders (11). Detailed information was available from 8 of 14 affected males (this is an X-linked disorder, so only males are affected). Cardiovascular difficulty was also later described (15). The most prominent and distinctive behavioral problem was overt antisocial conduct with excessive, sometimes violent aggression, often triggered by anger. Recorded incidents included stabbing, fighting, attempted rape, and other forced sexual activity. Other abnormal behaviors included arson, exhibitionism, and voyeurism. Except for a unilateral clubfoot in one affected male, no other congenital abnormalities or dysmorphic features were noted. No description was provided of early childhood behavioral characteristics of affected boys. Unaffected males and obligate female carriers within the family functioned normally.
Most of the well-described confirmed cases of isolated MAO-A deficiency have derived from the same family, reported in the two seminal papers in 1993 by Brunner and colleagues (11; 10); consequently, this disorder has sometimes been called "Brunner syndrome" after the first author of the original reports, including in reports from Brunner's own research group (06; 79).
In another family, a 5-year-old boy had developmental delay, autistic features, and myoclonic epilepsy, and his mother had mild intellectual disability and recurrent episodes of palpitations, headache, abdominal pain, and abdominal bloating (53). Whole exome sequencing identified the maternally-inherited variant c.410A>G, (p.Glu137Gly) in the MAOA gene. Biochemical studies confirmed MAOA deficiency in the child and his mother. Serotonergic symptoms and high serotonin levels were present in the mother. Treatment with a serotonin reuptake inhibitor and dietary modification produced regression of the biochemical abnormalities and partial reduction of symptoms.
Isolated MAO-B deficiency. No specific defect affecting only MAO-B without involvement of the Norrie gene has been described.
Combined MAO-A and B deficiency (without Norrie disease). In 2010, two males were described with a 240kb deletion of Xp11.3-p11.4 that included both MAO-A and B genes but excluded the Norrie disease gene (86; 85). A similar case was reported in 2012 (59). All had developmental delay, intermittent hypotonia, and stereotypic hand movements. Two brothers presented with severe mental retardation, hand wringing, intermittent hypotonia, lip smacking, and epilepsy (86; 85), and the same phenotype was seen in the son of another family, except epilepsy was not noted (59).
Norrie disease (OMIM 300658). Norrie disease is an X-linked recessive disorder characterized by very early childhood blindness due to degenerative and proliferative changes of the retina, hearing loss, and variable mental retardation. Norrie disease is caused by a mutation in the NDP gene on Xp11, which encodes norrin. The significance of Norrie disease in the present context is that genetic defects of MAO-A and B may co-occur with Norrie disease (26; 71; 72), but Norrie disease may occur without affecting either MAO-A or -B (49).
MAO-B deficiency with Norrie disease. The neurochemical and behavioral abnormalities seen in MAO-A deficiency were not found in two brothers who had MAO-B deficiency associated with Norrie disease (03; 44). Behavior was normal, and both brothers had completed university degrees; the only clinical problems were blindness and deafness, which are features of Norrie disease. Coexistence of cataplexy and abnormal REM sleep organization has also been linked to MAO-B deficiency in boys with Norrie disease (81).
Combined monoamine oxidase-A and B deficiency with Norrie disease. Combined MAO-A and B deficiency with Norrie disease often results in growth failure, severe mental retardation, autistic symptoms, autistic-like behavior, abnormal peripheral autonomic function, atonic seizures, and altered sleep patterns (42; 43; 71; 72; 54; 23; 44),
Other possible cases. In 2001, another family was reported in whom MAO deficiency was suspected based on elevated serum serotonin concentrations. The affected mother presented with a history of flushes, headaches, and diarrhea. Her two sons had moderate intellectual impairment and attention deficit and hyperactivity disorder (19). Discussion relating to this family pointed out that similar cases had been previously described (83). In one study, nine individuals exhibited the same features: chronic episodic flushing, diarrhea, headache, psychiatric symptoms, irritability, prostration, increased blood serotonin, and normal or subnormal urinary 5-HIAA concentrations. MAO deficiency was suspected, and metabolic studies supported the MAO deficiency hypothesis (82; 33). Confirmation of the condition by enzyme or mutation analysis was not reported in any of these studies.
Prognosis and complications
Complications of monoamine oxidase deficiency, other than those that occur as a direct manifestation of the disease, have not been described. Potentially lethal hypertensive crises may result through an increased sensitivity to dietary or pharmacological amines (10). In the case of monoamine oxidase-A deficiency, incarceration is likely due to the behavioral abnormalities associated with the disease.
Clinical vignette
Monoamine oxidase-A deficiency is an X-linked disease, and a single large Dutch family has been investigated (11). Evidence for monoamine oxidase deficiency was achieved by a finding of a maximum multipoint LOD score of 3.69 using a CA-repeat polymorphism in the structural gene for monoamine oxidase-A, elevated urinary concentrations of monoamine oxidase-A substrates (normetanephrine, 3-methoxytyramine, and tyramine), and reduced urinary concentrations of the monoamine oxidase-A products (vanillylmandelic acid, homovanillic acid, and 5-hydroxyindolacetic acid) (11). Confirmation monoamine oxidase-A deficiency was obtained by finding zero activity of this enzyme in dexamethasone-stimulated fibroblasts (10) and localization of a nonconservative C-to-T mutation, which caused a change of a glutamine codon (cytosine-adenosine-guanine) to a termination codon (thymidine-adenosine-guanine) at position 296 of the deduced amino acid sequence (10).
Detailed information was available from eight of 14 affected males. Early case details are not available. All had mild mental retardation with IQ scores around 85. No consistent congenital abnormalities or specific dysmorphic signs were noted. Clubfoot was present in one individual. No specific dysmorphic signs were present. All had a tendency toward stereotyped hand movements (eg, hand wringing, plucking, or fiddling), and all had behavioral problems with repeated occurrences of aggression. Aggressive behavior tended to occur during periods of 1 to 3 days and was associated with reduced sleep and night terrors. Abnormal behavior included the following: attempted rape, repeated fighting, stabbing, arson, exhibitionism, voyeurism, and sexual advances to female family members (11).
Biological basis
Etiology and pathogenesis
|
• Monoamine oxidase deficiency is inherited as an X-linked trait. | |
|
• Monoamine oxidase exists in two distinct forms encoded by separate genes, monoamine oxidase-A and monoamine oxidase-B, and each has preferential affinities for biogenic amine and other amine substrates. | |
|
• Monoamine oxidase deficiency has been described as an isolated monoamine oxidase-A deficiency, as a combined monoamine oxidase-A and B deficiency, as a combined monoamine oxidase-A and B deficiency in association with Norrie disease, and as an isolated monoamine oxidase-B deficiency in association with Norrie disease. | |
|
• Individuals with monoamine oxidase deficiency should avoid foods or drugs containing amines. |
Biochemistry and molecular biology of monoamine oxidases. Monoamine oxidases (EC 1.4.3.4) are a family of mitochondrial-bound flavoproteins that catalyze the oxidative deamination of a variety of biogenic amines to the corresponding aldehydes; the substrates for monoamine oxidases include monoamine neurotransmitters and neuromodulators (eg, histamine; the catecholamines—dopamine, norepinephrine, and epinephrine; and the substituted tryptamines—serotonin and melatonin), and many minor amines (eg, tryptamine and phenylethylamine) (84).
This reaction requires flavin adenine dinucleotide (FAD) as a covalently bound redox cofactor.
Oxidative deamination by monoamine oxidases involves three main steps: (1) after formation of an FAD-substrate adduct (ie, addition of two or more distinct molecules to form a single reaction product containing all atoms of all of the components) the FAD cofactor is reduced to FADH2 whereas the substrate amine is converted to an imine (ie, a functional group containing a carbon-nitrogen double bond); (2) the imine then dissociates from the enzyme and spontaneously hydrolyzes, producing an aldehyde and ammonium; and (3) FADH2 is reoxidized to FAD, with the formation of hydrogen peroxide from molecular oxygen (08).
|
(1) MAO-FAD + RCH2NH2 ⇒ MAO-FADH2-RCH=NH |
The overall reaction is:
|
• RCH2NH2 + O2 + H3O+ ⇒ RCHO + NH4+ + H2O2 |
Monoamine oxidase is functionally coupled with either an NAD(P)+-dependent aldehyde dehydrogenase (ALDH), which oxidizes the toxic aldehyde products of the monoamine oxidase reaction to the corresponding carboxylic acids, or aldehyde reductase or alcohol dehydrogenase, which reduce the toxic products to alcohols or glycols (a 1,2-diol; ie, an alcohol with 2 hydroxyl groups on adjacent carbon atoms) (58; 08).
Two forms of the enzyme are expressed in most tissues in the outer membrane of the mitochondria; they are designated monoamine oxidase A and monoamine oxidase B based on their differential sensitivity to inhibitors and their preferential affinity for substrates (37; 39). Monoamine oxidase A has a very high affinity for serotonin (120-fold higher than monoamine oxidase B) and, to a lesser degree, norepinephrine, whereas the preferred substrates of monoamine oxidase B are phenylethylamine and benzylamine. The substrate preferences of these isoenzymes are not absolute, and in the absence of one isoenzyme, the other can deaminate some of the available nonpreferred monoamine substrates (16).
The monoamine oxidase A and monoamine oxidase B are both anchored to the mitochondrial outer membrane through a transmembrane helix within the carboxyl-terminal domain. In their membrane-bound conformations, monoamine oxidase A and monoamine oxidase B are both dimeric (50; 25; 04; 78; 28).
Although both isoenzymes are expressed in most tissues, monoamine oxidase A is the only isoenzyme that is abundant in fibroblasts and placenta, and monoamine oxidase B is the only isoenzyme expressed in platelets and lymphocytes (27). In the brain, monoamine oxidase A is found mainly in dopaminergic and noradrenergic neurons, whereas monoamine oxidase B is the only isoenzyme expressed in the cell bodies of serotonergic and histaminergic neurons and astrocytes (41).
The differences in neurochemical profiles suggest that monoamine oxidase A normally plays a more important role than monoamine oxidase B in the metabolism of the biogenic amines, which is supported by the more severe clinical phenotype seen in the individuals with either monoamine oxidase A deficiency or combined monoamine oxidase A and B deficiency.
Monoamine oxidase B was thought to be involved in dopamine degradation, in large part because the therapeutic efficacy of monoamine oxidase B inhibitors in Parkinson disease was attributed to an increase in extracellular dopamine concentration. However, monoamine oxidase A, but not monoamine oxidase B, mainly contributes to striatal dopamine degradation (20). In contrast, monoamine oxidase B, but not monoamine oxidase A, is responsible for astrocytic GABA-mediated tonic inhibitory currents in the striatum (as shown in rats) (20). Therefore, in opposition to the traditional belief, monoamine oxidase A regulates dopamine levels, whereas monoamine oxidase B controls tonic GABA levels (20).
Monoamine oxidase genes. The monoamine oxidase A and monoamine oxidase B genes (MAOA and MAOB, respectively) were cloned in 1988 (02). Both have been mapped to the X chromosome in the p11.3 region in a tail-to-tail arrangement with the 3’-coding sequences separated by about 50 kb (42; 45; 18).
The monoamine oxidase A and monoamine oxidase B genes encode for proteins of 527 and 520 amino acids, with molecular weights of 59.7 and 58.8 kDa, respectively. The 3-dimensional structures of these enzymes have been elucidated (25).
The monoamine oxidase A and monoamine oxidase B genes share approximately 70% overall homology (ie, sequence similarity) and an identical intron-exon organization, each with 15 exons and 14 introns (17). The similarity of the two genes resulted from a common origin: both genes derive from duplication of a common ancestor gene (35).
The coding sequence in the human monoamine oxidase A gene is highly conserved, and observed polymorphisms either affect the third codon position and do not alter the deduced amino acid sequence or should not affect the structure of the protein (75). However, a variable tandem repeat polymorphism exists in the monoamine oxidase A promoter. The polymorphism consists of a repeated sequence present in 3, 3.5, 4, or 5 copies. Alleles with 3.5 or 4 copies are transcribed more efficiently than those with three or five copies of the repeat (69), and the variations have been associated with behavior traits such as impulsivity, hostility, and aggression (51; 14).
Monoamine oxidase disorders. The concentrations of monoamine oxidase A and monoamine oxidase B differ widely in humans, and some variations may predispose individuals to various neurologic and psychiatric diseases, including alcoholism (74), depression and alcoholism (80; 55), bipolar disorder (47; 48; 38; 67; 30; 65), schizophrenia (89), impulsive aggressiveness, antisocial personality (68; 24; 61; 12; 87), and attention-deficit/hyperactivity disorder (46; 66; 56).
Aggressive behavior in animals and humans has been linked to central and peripheral changes in serotonin, dopamine, and norepinephrine metabolism (88; 21; 76; 63; 52; 13). Congenital monoamine oxidase A deficiency and low-activity monoamine oxidase A variants are both associated with a higher risk for antisocial behavior and violence, particularly in males with a history of child maltreatment (40). This is a well-documented example of a gene-environment interaction, ie, a differential effect of a genotype on disease risk in persons with different environmental exposures.
Affected males with X-linked monoamine oxidase A deficiency (Brunner syndrome) had a marked disturbance in their urinary monoamine profile that was compatible with a defect in monoamine oxidase (11). The same group later reported that monoamine oxidase A activity was deficient in dexamethasone-stimulated cultured skin fibroblasts from affected males and that monoamine oxidase B activity was normal (10). The deficient monoamine oxidase A activity was caused by a truncating point mutation (c.886C> T [p.Gln296*]) in exon 8 of the monoamine oxidase A structural gene (MAOA) on chromosome Xp11.3, which changes a glutamine (cytosine-adenosine-guanine) codon to a termination (thymidine-adenosine-guanine) codon (10).
Monoamine oxidase A mutations in Brunner syndrome apparently increase the activity of dopaminergic neurons through upregulation of NMDAR (ie, the N-methyl-D-aspartate receptor) (79).
Two additional families have been identified, if not fully reported; one family was reported with a pathogenic missense mutation (c.797_798GC> TT [p.Cys266Phe]) associated with deficient monoamine oxidase A activity in a family affected by autism, intellectual disability, and abnormal behavior, consistent with the findings of Brunner and colleagues from 1993 (11; 10; 62).
Deficiency of monoamine oxidase A leads to increased urinary concentrations of its substrates, normetanephrine, 3-methoxytyramine, serotonin, and tyramine, and reduced urinary concentrations of the amine metabolites, vanillylmandelic acid, homovanillic acid, 3-methoxy-4-hydroxyphenolglycol, and 5-hydroxyindoleacetic acid (11; 01; 44).
Molecular simulations of the rate-limiting step of MAO-A-catalyzed serotonin degradation for known Brunner syndrome MAOA variants showed that the R45W mutation causes a 6000-fold slowdown of enzymatic function, whereas the E446K mutation causes a 450-fold reduction of the serotonin degradation rate, both of which effectively function as a gene knockout (64).
-
Monoamine oxidase enzyme with serotonin docked in the active site and reacting with the flavin adenine dinucleotide cofactor
Monoamine oxidase enzyme with serotonin (SRO) docked in the active site (shown in inset on the left) and reacting with the flavin adenine dinucleotide (FAD) cofactor. The locations of the mutated residues of two mutation varian...
-
Scheme of the rate-limiting step of MAO-catalyzed serotonin degradation
Scheme of the rate-limiting step of MAO-catalyzed serotonin degradation, involving a hydride transfer between the reacting carbon atom of serotonin (SRO) vicinal to the amino group, to the nitrogen atom of the flavin adenine di...
Norrie disease. Norrie disease is an X-linked recessive disease caused by loss-of-function mutations in the Norrie disease pseudoglioma gene on chromosome Xp11.4, which encodes the protein norrin. Males with Norrie disease have childhood blindness due to degenerative and proliferative changes of the retina, and many develop sensorineural deafness and a progressive mental disorder, often with psychotic features.
MAO-B deficiency with Norrie disease. Two brothers (ages 29 and 31 years) were reported with a complete selective loss of monoamine oxidase B activity due to a microdeletion of the Norrie disease and monoamine oxidase B genes (44). The distal deletion breakpoint lay in intron 5 of the monoamine oxidase B gene, with the deletion extending proximally into the Norrie gene (44). The two individuals with monoamine oxidase B deficiency combined with Norrie disease did not show the same neurochemical abnormalities that are seen in monoamine oxidase A deficiency but instead showed increased urinary phenylethylamine levels (44). Confirmation of monoamine oxidase B deficiency was obtained by measurement of the activity of this enzyme in platelets (44).
Combined monoamine oxidase A and B deficiency without Norrie disease. Combined monoamine oxidase A and B deficiency (in the absence of Norrie disease) in two families was caused by microdeletions in chromosome Xp11.3 exclusively encompassing the MAOA and MAOB genes (86; 85; 59).
Central monoamine neurotransmitter metabolism has not been investigated in individuals with monoamine oxidase A deficiency, but in an individual with combined monoamine oxidase A and B deficiency, the concentration of serotonin in cerebrospinal fluid was elevated, and concentrations of homovanillic acid (a dopamine metabolite) and 5-hydroxyindoleacetic acid (a serotonin metabolite) were undetectable (59). Therefore, altered central monoamine metabolism is likely responsible for the aggressive behavior seen in individuals with monoamine oxidase A deficiency; however, because monoamine oxidase A deficiency also raises serotonin concentrations, it provides an interesting exception to the low-serotonin paradigm of impulsive aggression (09). REM sleep deprivation may also be involved because monoamine oxidase A inhibitors suppress REM sleep in humans (22), and REM sleep deprivation produces shock-induced fighting in animals (77).
Animal models. Mouse models are available for deficiencies of monoamine oxidase A (13; 70; 05; 08), monoamine oxidase B (36), and combined monoamine oxidase A and B deficiency (16; 08; 59; 73; 57).
Most significantly, transgenic mice lacking monoamine oxidase A show violent behavior, providing confirmatory evidence for the link between abnormal behavior and monoamine oxidase A deficiency (13; 07; 40). Combined antagonism of 5-HT2 and NMDA receptors reduces the aggression of monoamine oxidase A knockout mice (29).
In MAO-B knockout mice, phenethylamine has been shown to be a substrate of monoamine oxidase B in the paraventricular thalamic nucleus, where the enzyme is highly expressed (57); phenylethylamine is likely a substrate of monoamine oxidase B in the paraventricular thalamic nucleus as well as other tissues.
Mice lacking monoamine oxidase A and monoamine oxidase B exhibit (1) decreased proliferation of neural stem cells beginning in late gestation and persisting into adulthood; (2) significantly increased monoamine levels, particularly serotonin; and (3) anxiety-like behaviors as adults (59).
Epidemiology
|
• Monoamine oxidase deficiency is a rare disease. |
Monoamine oxidase deficiency is a rare disease that has been incorporated into a worldwide research project focused on primary and secondary neurotransmitter disorders (60). A single large, Dutch kindred has been described with monoamine oxidase A deficiency (11). Three related boys and two brothers in a separate family have been described with monoamine oxidase B deficiency in association with Norrie disease (03; 44; 81). Three children from two families have been identified with combined monoamine oxidase-A and B deficiency in the absence of Norrie disease (86; 85; 59).
Differential diagnosis
Confusing conditions
The major symptoms of monoamine oxidase-A deficiency are mild mental retardation and behavioral abnormalities, mainly violent aggression (11). These clinical characteristics are nonspecific, but measurement of monoamine oxidase substrates and products in urine should differentiate individuals with monoamine oxidase-A deficiency from those with monoamine oxidase-B deficiency or other conditions. Monoamine oxidase-A deficiency leads to a characteristic elevation of urinary concentrations of the monoamine oxidase-A substrates, normetanephrine, 3-methoxytyramine, and tyramine, in combination with reduced amounts of the monoamine oxidase products, vanillylmandelic acid, homovanillic acid, 3-methoxy-4-hydroxyphenolglycol, and 5-hydroxyindoleacetic acid (11; 01).
A similar urinary pattern of biogenic amines and metabolites has been found in individuals with X chromosome deletions involving the Norrie disease gene and both the monoamine oxidase-A and monoamine oxidase-B structural genes (71; 72; 54; 23), and in individuals with combined monoamine oxidase-A and B deficiency in the absence of Norrie disease (86; 59). Isolated monoamine oxidase-A deficiency and combined monoamine oxidase-A and B deficiency can be distinguished from those with Norrie disease because Norrie syndrome is characterized by congenital blindness and progressive deafness (26; 71; 72). The concentrations of the above amines and metabolites are normal in individuals with monoamine oxidase-B deficiency who have no behavioral or mental problems. The only biochemical abnormality in monoamine oxidase B deficiency is an increase in the concentration of urinary phenylethylamine (44).
Urinary concentrations of all monoamine oxidase products are also reduced in conditions affecting the overall biosynthesis and turnover of serotonin and the catecholamines. These include the inborn errors that affect tetrahydrobiopterin metabolism and aromatic L-amino acid decarboxylase (32). Individuals with these conditions usually present in early infancy, and often with severe neurologic impairment; however, cases with only mild neurologic symptoms have been reported. A decrease in the urinary concentrations of the monoamine oxidase substrates, as well as the metabolites, distinguishes these conditions from monoamine oxidase deficiency.
Other conditions associated with altered behavior and changes in biogenic amine metabolism include pheochromocytoma, neuroblastoma, and diseases such as Parkinson disease, where a specific defect affects the nigrostriatal dopamine system. In these, as well as most other conditions affecting biogenic amine metabolism, either a combined decrease or increase of monoamine oxidase substrates and products takes place.
Diagnostic workup
|
• Monoamine oxidase-A deficiency should be considered in any X-linked condition that shows linkage to proximal Xp as well as in families where male members show prominent behavioral disturbance. | |
|
• Measurement of neurotransmitters and metabolites in urine can identify the disease and distinguish between affected males, carrier females, and normal controls. | |
|
• Monoamine oxidase-A deficiency causes an increase in the urinary concentrations of the monoamine oxidase substrates, serotonin, normetanephrine, 3-methoxytyramine, and tyramine, and a reduction in the concentrations of the monoamine oxidase products, vanillylmandelic acid, homovanillic acid, 3-methoxy-4-hydroxyphenolglycol, and 5-hydroxyindoleacetic acid. | |
|
• Monoamine oxidase A deficiency can be confirmed by measurement of the enzyme activity in dexamethasone-stimulated fibroblasts. | |
|
• Monoamine oxidase-B deficiency has only been described in association with Norrie disease. |
Positive diagnosis of monoamine oxidase-A deficiency has only been reported in detail in one kindred in which males affected by the disease presented with mild mental retardation and violent aggressive behavior (11).
Nevertheless, monoamine oxidase-A deficiency should be considered in any X-linked condition that shows linkage to proximal Xp (11) as well as in families where male members show prominent behavioral disturbance. Measurement of neurotransmitters and metabolites in urine can identify the disease and distinguish between affected males, carrier females, and normal controls (11; 01; 44). It is important that subjects not eat amine-rich foods (ie, bananas or dates) prior to testing. Monoamine oxidase-A deficiency causes an increase in the urinary concentrations of the monoamine oxidase substrates, serotonin, normetanephrine, 3-methoxytyramine, and tyramine, and a reduction in the concentrations of the monoamine oxidase products, vanillylmandelic acid, homovanillic acid, 3-methoxy-4-hydroxyphenolglycol, and 5-hydroxyindoleacetic acid (11; 01). Monoamine oxidase A deficiency can be confirmed by measurement of the enzyme activity in dexamethasone-stimulated fibroblasts (10). Monoamine oxidase A activity cannot be used to detect carrier females, as their activities fall in the control range (10).
Monoamine oxidase-B deficiency has only been described in association with Norrie disease (03; 44; 81). The major clinical symptoms are those associated with Norrie disease. Clinical features that might be found in an isolated case of monoamine oxidase B deficiency are unknown but may include cataplexy and abnormal REM sleep (81). Increased urinary phenylethylamine should raise suspicion of monoamine oxidase B deficiency, which could be confirmed by measuring enzyme activity in platelets (44).
Combined monoamine oxidase-A and B deficiency (in the absence of Norrie disease) has been described in two families. Three affected male children showed intermittent hypotonia, stereotypic hand movements, and developmental delay. Array comparative genomic hybridization (86; 85) and-oligonucleotide-SNP chromosomal microarray (59) were used to identify two separate microdeletions in the region chromosome Xp11.3-p11.4 that encompassed both monoamine oxidase-A and B. Urine and cerebrospinal fluid were examined from one child. Urinary neurotransmitters and metabolites resembled those seen in the individuals with monoamine oxidase-A deficiency, and cerebrospinal fluid showed elevation of serotonin and undetectable concentrations of the serotonin metabolite, 5-hydroxyindoleacetic acid, and the dopamine metabolite, homovanillic acid.
Management
|
• No specific treatment for monoamine oxidase deficiency has been described. | |
|
• In patients lacking normal monoamine oxidase A and monoamine oxidase B function, potentially lethal hypertensive crises may result through an increased sensitivity to dietary or pharmacological amines. | |
|
• Complications of these amine-induced hypertensive crises can include intracerebral hemorrhage, cardiac arrhythmias, and cardiac failure. | |
|
• Individuals with monoamine oxidase deficiency should avoid foods or drugs containing amines. |
No specific treatment for monoamine oxidase deficiency has been described.
Dietary intervention by avoiding foods rich in amines may be beneficial because monoamine oxidase A and monoamine oxidase B are essential for inactivating dietary and pharmacologic amines, including m-tyramine, p-tyramine, and phenylethylamine (44). In patients lacking normal monoamine oxidase A and monoamine oxidase B function, potentially lethal hypertensive crises may result through an increased sensitivity to dietary or pharmacological amines (10). Tyramine and phenylethylamine can cause hypertensive crises by acting as indirect sympathomimetics at sympathetic nerve terminals and in the adrenal glands (34). Complications of these amine-induced hypertensive crises can include intracerebral hemorrhage, cardiac arrhythmias, and cardiac failure (34). Affected individuals should not eat aged and fermented foods that contain high amounts of tyramine (59). In particular, aged cheeses (eg, blue, cheddar, Swiss, Gorgonzola, Gouda, Parmesan, Romano, feta, and Brie) and aged, dried, fermented, pickled meats (eg, bacon, sausage, liverwurst, pepperoni, salami, ham, hot dogs, and corned beef) must be avoided.
Special considerations
Anesthesia
Because of the behavior abnormalities, many procedures, even dental procedures, require special management. Furthermore, anesthesia presents serious risks of fatal arrhythmias in monoamine oxidase A deficiency. Successful anecdotal management with general anesthesia for dental treatment in a patient with MAO-A and MAO-B deficiency has been reported (31).
Media
References
- 01
- Abeling NG, van Gennip AH, Overmars H, van Oost B, Brunner HG. Biogenic amine metabolite patterns in the urine of monoamine oxidase A-deficient patients. A possible tool for diagnosis. J Inherit Metab Dis 1994;17:339-41. PMID 7807947
- 02
- Bach AW, Lan NC, Johnson DL, et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A 1988;85(13):4934-8. PMID 3387449
- 03
- Berger W, Meindl A, van de Pol TJ, et al. Isolation of a candidate gene for Norrie disease by positional cloning. Nat Genet 1992;1:199-203. PMID 1303235
- 04
- Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50(23):5848-52. PMID 17915852
- 05
- Bortolato M, Chen K, Godar SC, et al. Social deficits and perseverative behaviors, but not overt aggression, in MAO-A hypomorphic mice. Neuropsychopharmacology 2011a;36(13):2674-88. PMID 21832987
- 06
- Bortolato M, Floris G, Shih JC. From aggression to autism: new perspectives on the behavioral sequelae of monoamine oxidase deficiency. J Neural Transm (Vienna) 2018;125(11):1589-99. PMID 29748850
- 07
- Bortolato M, Godar SC, Alzghoul L, et al. Monoamine oxidase A and A/B knockout mice display autistic-like features. Int J Neuropsychopharmacol 2013;16(4):869-88. PMID 22850464
- 08
- Bortolato M, Shih JC. Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int Rev Neurobiol 2011b;100:13-42. PMID 21971001
- 09
- Brunner HG. MAOA deficiency and abnormal behaviour: perspectives on an association. Ciba Found Symp 1996;194:155-64. PMID 8862875
- 10
- Brunner HG, Nelen M, Breakefiald XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993b;262:578-80. PMID 8211186
- 11
- Brunner HG, Nelen MR, van Zandvoort P, et al. X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet 1993a;52:1032-9. PMID 8503438
- 12
- Buckholtz JW, Meyer-Lindenberg A. MAOA and the neurogenetic architecture of human aggression. Trends Neurosci 2008;31(3):120-9. PMID 18258310
- 13
- Cases O, Seif I, Grimsby J, et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAO-A. Science 1995;268:1763-6. PMID 7792602
- 14
- Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science 2002;297:851-4. PMID 12161658
- 15
- Chen ZY, Denney RM, Breakefield XO. Norrie disease and MAO genes: nearest neighbors. Hum Mol Genet 1995;4:1729-37. PMID 8541872
- 16
- Chen K, Holschneider DP, Wu W, Rebrin I, Shih JC. A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. J Biol Chem 2004;279(38):39645-52. PMID 15272015
- 17
- Chen ZY, Hotamisligil GS, Huang JK, et al. Structure of the human gene for monoamine oxidase type A. Nucleic Acids Res 1991;19:4537-41. PMID 1886775
- 18
- Chen ZY, Powell JF, Hsu YP, Breakefield XO, Craig IW. Organization of the human monoamine oxidase genes and long-range physical mapping around them. Genomics 1992;14(1):75-82. PMID 1427833
- 19
- Cheung NW, Earl J. Monoamine oxidase deficiency: a cause of flushing and attention-deficit/hyperactivity disorder. Arch Int Med 2001;161(20):2503-4. PMID 11700166
- 20
- Cho HU, Kim S, Sim J, et al. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis. Exp Mol Med 2021;53(7):1148-58. PMID 34244591
- 21
- Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry 1989;155(Suppl 8):52-62. PMID 2692640
- 22
- Cohen RM, Pickar D, Garrett D, et al. REM sleep suppression induced by selective monoamine oxidase inhibition. Psychopharmacol 1982;78:137-40. PMID 6817370
- 23
- Collins FA, Murphy DL, Reiss AL, et al. Clinical, biochemical, and neuropsychiatric evaluation of a patient with contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. Am J Med Genet 1992;42:127-34. PMID 1308352
- 24
- Contini V, Marques FZ, Garcia CE, Hutz MH, Bau CH. MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 2006;141B(3):305-8. PMID 16526025
- 25
- De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci U S A 2005;102(36):12684-9. PMID 16129825
- 26
- de la Chapelle A, Sankila EM, Lindlof M, Aula P, Norio R. Norrie disease caused by a gene deletion allowing carrier detection and prenatal diagnosis. Clin Genet 1985;28:317-20. PMID 2998655
- 27
- Donnelly CH, Murphy DL. Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 1977;26(9):853-8. PMID 861051
- 28
- Edmondson DE, Binda C, Wang J, Upadhyay AK, Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 2009;48:4220-30. PMID 19371079
- 29
- Frau R, Pardu A, Godar S, Bini V, Bortolato M. Combined antagonism of 5-HT2 and NMDA receptors reduces the aggression of monoamine oxidase a knockout mice. Pharmaceuticals (Basel) 2022;15(2):213. PMID 35215325
- 30
- Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC. Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta-analyses, and sequencing of the promoter. Am J Med Genet 1999;88(4):398-406. PMID 10402508
- 31
- Hoshijima H, Takeuchi R, Kikuchi K, Mizuta K. Anesthetic management in MAO-A and MAO-B deficiency: a case report. J Anesth 2020;34(5):773-76. PMID 32504152
- 32
- Hyland K. Abnormalities of biogenic amine metabolism. J Inherit Metab Dis 1993;16(4):676-90. PMID 8412014
- 33
- Giannini AJ, Malone DA, Piotrowski TA. The serotonin irritation syndrome: a new clinical entity. J Clin Psychiatry 1986;47:22-5. PMID 2416736
- 34
- Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol 2011;31(1):66-74. PMID 21192146
- 35
- Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC. Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci U S A 1991;88(9):3637-41. PMID 2023912
- 36
- Grimsby J, Toth M, Chen K, et al. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet 1997;17(2):206-10. PMID 9326944
- 37
- Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17(7):1285-97. PMID 5659776
- 38
- Kawada Y, Hattori M, Dai XY, Nanko S. Possible association between monoamine oxidase A gene and bipolar affective disorder. Am J Hum Genet 1995;56(1):335-6. PMID 7880306
- 39
- Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408. PMID 5066229
- 40
- Kolla NJ, Bortolato M. The role of monoamine oxidase A in the neurobiology of aggressive, antisocial, and violent behavior: a tale of mice and men. Prog Neurobiol 2020;194:101875. PMID 32574581
- 41
- Konradi C, Kornhuber J, Froelich L, et al. Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 1989;33(2):383-400. PMID 2622533
- 42
- Lan NC, Chen CH, Shih JC. Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J Neurochem 1989a;52:1652-4. PMID 2496202
- 43
- Lan NC, Heinzman C, Gal A, et al. Human monoamine oxidase A and B genes map to xp11.23 and are deleted in a patient with Norrie disease. Genomics 1989b;4:552-9. PMID 2744764
- 44
- Lenders JW, Eisenhofer G, Abeling NG, et al. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 1996;97:1010-6. PMID 8613523
- 45
- Levy ER, Powell JF, Buckle VJ, et al. Localization of human monoamine oxidase-A gene to Xp11.23-11.4 by in situ hybridization: implications for Norrie disease. Genomics 1989;5:368-70. PMID 2793188
- 46
- Li J, Wang Y, Hu S, et al. The monoamine oxidase B gene exhibits significant association to ADHD. Am J Med Genet B Neuropsychiatr Genet 2008;147(3):370-4. PMID 17918234
- 47
- Lim LC, Powell JF, Murray R, Gill M. Monoamine oxidase A gene and bipolar affective disorder. Am J Hum Genet 1994;54(6):1122-4. PMID 8018211
- 48
- Lim LC, Powell J, Sham P, et al. Evidence for genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. Am J Med Genet 1995;60(4)325-31. PMID 7485270
- 49
- Liu J, Zhu J, Yang J, Zhang X, Zhang Q, Zhao P. Prenatal diagnosis of familial exudative vitreoretinopathy and Norrie disease. Mol Genet Genomic Med 2019;7(1):e00503. PMID 30474316
- 50
- Ma J, Yoshimura M, Yamashita E, Nakagawa A, Ito A, Tsukihara T. Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J Mol Biol 2004;338(1):103-14. PMID 15050826
- 51
- Manuck SB, Flory JD, Ferrell RE, Mann JJ, Muldoon MF. A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatry Res 2000;95:9-23. PMID 10904119
- 52
- Mehlman PT, Higley JD, Faucher I, et al. Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in non-human primates. Am J Psychiatry 1994;151:1485-91. PMID 7522411
- 53
- Minniti ML, Kalantari S, Pasca L, et al. Expanding the phenotype of Brunner syndrome from childhood to adulthood: Description of the second pediatric patient and his mother. Am J Med Genet A 2024;194(1):82-7. PMID 37750385
- 54
- Murphy DL, Sims KB, Karoum F, et al. Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neurochem 1990;54:242-7. PMID 2293615
- 55
- Naoi M, Maruyama W, Shamoto-Nagai M. Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis. J Neural Transm (Vienna) 2018;125(1):53-66. PMID 28293733
- 56
- Nymberg C, Jia T, Lubbe S, et al. Neural mechanisms of attention-deficit/hyperactivity disorder symptoms are stratified by MAOA genotype. Biol Psychiatry 2013;74(8):607-14. PMID 23746540
- 57
- Obata Y, Kubota-Sakashita M, Kasahara T, Mizuno M, Nemoto T, Kato T. Phenethylamine is a substrate of monoamine oxidase B in the paraventricular thalamic nucleus. Sci Rep 2022;12(1):17. PMID 34996979
- 58
- O’Brien PJ, Siraki AG, Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 2005;35(7):609-662. PMID 16417045
- 59
- O’Leary RE, Shih JC, Hyland K, Kramer N, Asher YJ, Graham JM. De novo microdeletion of Xp11.3 exclusively encompassing the monoamine oxidase A and B genes in a male infant with episodic hypotonia: A genomics approach to personalized medicine. Eur J Med Genet 2012:55:349-53. PMID 22365943
- 60
- Opladen T, Cortès-Saladelafont E, Mastrangelo M, et al. The International Working Group on Neurotransmitter related Disorders (iNTD): a worldwide research project focused on primary and secondary neurotransmitter disorders. Mol Genet Metab Rep 2016;9:61-6. PMID 27830117
- 61
- Oreland L, Nilsson K, Damberg M, Hallman J. Monoamine oxidases: activities, genotypes and the shaping of behaviour. J Neural Transm 2007;114(6):817-22. PMID 17426915
- 62
- Piton A, Redin C, Mandel JL. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. Am J Hum Genet 2013;93(2):368-83. Erratum in: Am J Hum Genet 2013;93(2):406. PMID 23871722
- 63
- Popova NK, Nikulina EM, Kulikov AV. Genetic analysis of different kinds of aggressive behavior. Behav Genet 1993;23:491-7. PMID 8267559
- 64
- Prah A, Pregeljc D, Stare J, Mavri J. Brunner syndrome caused by point mutation explained by multiscale simulation of enzyme reaction. Sci Rep 2022;12(1):21889. PMID 36536002
- 65
- Preisig M, Bellivier F, Fenton BT, et al. Association between bipolar disorder and monoamine oxidase A gene polymorphisms: results of a multicenter study. Am J Psychiatry 2000;157(6):948-55. PMID 10831475
- 66
- Ribasés M, Ramos-Quiroga JA, Hervás A, et al. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol Psychiatry 2009;14(1):71-85. PMID 17938636
- 67
- Rubinsztein DC, Leggo J, Goodburn S, Walsh C, Jain S, Paykel ES. Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis. Hum Mol Genet 1996;5(6):779-82. PMID 8776592
- 68
- Samochowiec J, Lesch KP, Rottmann M, et al. Association of a regulatory polymorphism in the promoter region of the monoamine oxidase A gene with antisocial alcoholism. Psychiatry Res 1999;86(1):67-72. PMID 10359483
- 69
- Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998;103:273-9. PMID 9799080
- 70
- Scott AL, Bortolato M, Chen K, Shih JC. Novel monoamine oxidase A knock out mice with human-like spontaneous mutation. Neuroreport 2008;19(7):739-43. PMID 18418249
- 71
- Sims KB, de la Chapelle A, Norio R, et al. Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 1989a;2:1069-76. PMID 2483108
- 72
- Sims KB, Ozelius L, Corey T, et al. Norrie disease gene is distinct from the monoamine oxidase genes. Am J Hum Genet 1989b;45(3):424-34. PMID 2773935
- 73
- Singh C, Bortolato M, Bali N, et al. Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice. Proc Natl Acad Sci U S A 2013;110(31):12816-21. PMID 23858446
- 74
- Tabakoff B, Hoffman PL, Lee JM, et al. Differences in platelet enzyme activity between alcoholics and non-alcoholics. N Engl J Med 1988;318:134-9. PMID 3336400
- 75
- Tivol EA, Shalish C, Schuback DE, Hsu YP, Breakefield XO. Mutational analysis of the human MAOA gene. Am J Med Genet 1996;67:92-7. PMID 8678123
- 76
- Troncone LR, Tufik S. Effects of selective adrenoceptor agonists and antagonists on aggressive behavior elicited by apomorphine, DL-dopa and fusaric acid in REM sleep deprived rats. Physiol Behav 1991;50:173-8. PMID 1946713
- 77
- Tufik S, Lindsey CJ, Carlini EA. Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain. Pharmacology 1978;16:98-105. PMID 201949
- 78
- Upadhyay AK, Wang J, Edmondson DE. Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms. Biochemistry 2008;47(2):526-36. PMID 18092818
- 79
- van Rhijn JR, Shi Y, Bormann M, et al. Brunner syndrome associated MAOA mutations result in NMDAR hyperfunction and increased network activity in human dopaminergic neurons. Neurobiol Dis 2022;163:105587. PMID 34923109
- 80
- von Knorring L, Perris C, Oreland L, et al. Morbidity risk for psychiatric disorders in families of probands with affective disorders divided according to levels of platelet MAO activity. Psychiatry Res 1985;15:271-9. PMID 3865245
- 81
- Vossler DG, Wyler AR, Wilkus RJ, Gardner-Walker G, Vlcek BW. Cataplexy and monoamine oxidase deficiency in Norrie disease. Neurology 1996;46:1258-61. PMID 8628463
- 82
- Warner RR. Hyperserotoninemia in functional gastrointestinal disease. Ann Intern Med 1963;59:464-76. PMID 14067469
- 83
- Warner RR. Monoamine oxidase deficiency: a cause of symptomatic hyperserotoninemia in the absence of carcinoid. Arch Intern Med 2002;162:1647-8. PMID 12123415
- 84
- Weyler W, Hsu YP, Breakefield XO. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 1990;47:391-417. PMID 2290855
- 85
- Whibley AC, Plagnol V, Tarpey PS, et al. Fine-scale survey of X chromosome copy number variants and indels underlying intellectual disability. Am J Hum Genet 2010b;87(2):173-88. PMID 20655035
- 86
- Whibley A, Urquhart J, Dore J, et al. Deletion of MAOA and MAOB in a male individual causes severe developmental delay, intermittent hypotonia and stereotypical hand movements. Eur J Hum Genet 2010a;18:1095-9. PMID 20485326
- 87
- Williams LM, Gatt JM, Kuan SA, et al. A polymorphism of the MAOA gene is associated with emotional brain markers and personality traits on an antisocial index. Neuropsychopharmacology 2009;34(7):1797-809. PMID 19194374
- 88
- Winslow JT, Miczek KA. Habituation of aggression in mice: pharmacological evidence of catecholaminergic and serotonergic mediation. Psychopharmacology (Berl) 1983;81:286-91. PMID 6419256
- 89
- Zureick JL, Meltzer HY. Platelet MAO activity in hallucinating and paranoid schizophrenia: a review and meta-analysis. Biol Psychiatry 1988;24:63-78. PMID 3285902
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Douglas J Lanska MD MS MSPH
Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile
Former Authors
- Keith Hyland PhD
Patient Profile
- Age range of presentation
-
- 0 month to 18 years
- Sex preponderance
-
- male>female, >2:1
- Heredity
-
- heredity typical
- heredity may be a factor
- X-linked
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Metabolic disorder, unspecified: E88.9
- ICD-11
-
- Other specified disorders of biogenic amine metabolism: 5C59.0Y
- OMIM
-
- Brunner syndrome: 300615
- Monoamine oxidase-A: *309850
- NDP gene: 300658
- Norrie disease: 310600
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neurogenetic Disorders
GABA-transaminase deficiency
Nov. 27, 2024
-
Neurogenetic Disorders
Carnitine palmitoyltransferase II deficiency
Nov. 24, 2024
-
Neurogenetic Disorders
Biotinidase deficiency
Nov. 09, 2024
-
Neurogenetic Disorders
Propionyl-CoA carboxylase deficiency
Nov. 09, 2024
-
Neurogenetic Disorders
Pyruvate carboxylase deficiency
Nov. 09, 2024
-
Neurogenetic Disorders
Isolated beta-methylcrotonyl-CoA carboxylase deficiency
Nov. 09, 2024
-
Neurogenetic Disorders
Pelizaeus-Merzbacher disease
Oct. 31, 2024